Dublin
Innovative Durvalumab mechanism of action in treating NSCLC
This is an immunotherapy injection that is given as an intravenous (IV) infusion. The durvalumab mechanism of action is blocking PD-L1 proteins. These proteins are responsible for turning off the immune system by binding to T-cells. However, after the blocking, the immune system gets activated and destroys the cancer cells. On the other hand, doctors recomme...
Check with seller
